logo
Farmers report difficult conditions that could have widespread impact on food prices: 'A thing of the past'

Farmers report difficult conditions that could have widespread impact on food prices: 'A thing of the past'

Yahoo19-03-2025

Warmer temperatures brought on by our shifting climate have forced farmers in central Nepal to move orange cultivation to higher altitudes, leading to declining yields in some areas.
As The Rising Nepal detailed, farmers grow oranges commercially on roughly 2,000 acres of land in the Myagdi District in west-central Nepal. However, with hotter weather becoming more common in the region, only about half the orange trees produce fruit.
Sanjeev Bastola, head of the agricultural knowledge center in Myagdi, explained that lower altitudes are becoming too warm for optimal orange growth.
"Although terrain of 900 to 1,500 meters above sea level is suitable for orange cultivation … recent production is good only above that altitude," he said.
Rising temperatures and drier soil have also destroyed orange trees in the nearby town of Maubaphant, where many homeowners grow oranges for their families to eat.
Resident Hari Subedi told The Rising Nepal that Maubaphant oranges used to be the talk of the town when the climate could support them. Now, Subedi said that has changed, with the publication summarizing his assessment as they are "now a thing of the past."
But even though farmers have had to shift production to higher altitudes, orange yields have surprisingly increased in Myagdi compared to last year. Farmers produced nearly 4,000 tons of oranges in 2024 and more than 5,000 tons this year, signaling hope that the region can adapt.
While some farmers at higher elevations benefit from rising temperatures, others in towns closer to sea level, such as Maubaphant, end up losing income and a staple crop for their families. Additionally, with fewer farmers cultivating oranges, it will drive prices up for locals who can no longer grow them in their backyards.
On a global scale, this could disrupt supply chains and lead to more expensive groceries in other regions that rely on Nepal for oranges.
Do you worry about the longevity of EV batteries?
For sure
Not really
Not at all
I've never thought about it
Click your choice to see results and speak your mind.
Orange trees are also important for ecological balance, helping to absorb excess carbon dioxide, provide food and shelter for birds and insects, and attract pollinators. With the climate causing shifts in growing regions, it may lead to imbalances in food chains and ecosystems.
Our overheating planet is making it harder to grow other staple crops worldwide, such as wheat, grapes (which also affects wine production), cocoa, cotton, coffee, and potatoes.
The Rising Nepal explained that better control of pests and diseases played a role in increasing yields, and farmers will likely continue to use this strategy. Local agricultural organizations have also been helping farmers by providing seeds and saplings and offering training programs on orchard management, irrigation, and marketing.
Some orange farmers in Spain have turned to growing mandarins after devastating floods impacted crop yields in late 2024. Scientists are also working on creating modified citrus trees that can withstand citrus greening, a disease that affects citrus growers worldwide.
It may seem off-topic, but we can help farmers by switching to all-electric appliances or installing solar panels, which reduce pollution and cool the planet. Knowledge is power, so staying informed about how the climate impacts crops can help you plan for possible changes to food supplies.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The Fire Protection Research Foundation and the Fire Safety Research Institute Issue Notice Around Potential Hazard Involving Fire Blankets Used for Electric Vehicle Fire Suppression Efforts with Battery Involvement
The Fire Protection Research Foundation and the Fire Safety Research Institute Issue Notice Around Potential Hazard Involving Fire Blankets Used for Electric Vehicle Fire Suppression Efforts with Battery Involvement

Yahoo

time30-05-2025

  • Yahoo

The Fire Protection Research Foundation and the Fire Safety Research Institute Issue Notice Around Potential Hazard Involving Fire Blankets Used for Electric Vehicle Fire Suppression Efforts with Battery Involvement

Key Takeaways: Experiments conducted by both organizations have demonstrated a potential explosion hazard when fire blankets are used during electric vehicle (EV) fire suppression efforts when there is battery involvement. When flaming is eliminated by the fire blanket, the ongoing accumulation of flammable gases released by continued thermal runaway in the battery pack presents a potential explosion risk. The experiments reinforce the need for continued research on EV firefighting tactics. QUINCY, Mass. and COLUMBIA, Md., May 30, 2025 /PRNewswire/ -- The Fire Protection Research Foundation (FPRF), the research affiliate of NFPA, and the Fire Safety Research Institute (FSRI), part of UL Research Institutes, today issued a notice about a potential explosion hazard when fire blankets are used during electric vehicle fire suppression efforts with battery involvement. During experiments involving the use of electric vehicle fire blankets to suppress an EV fire with battery involvement, it was observed that the deployment of a fire blanket eliminated flaming by denying oxygen to the vehicle and the battery fire. While the flaming was eliminated, battery thermal runaway propagation continued after blanket deployment, which resulted in the continued release and accumulation of flammable battery gases into the volume under the blanket In some of the experiments, this accumulation of flammable gases under the blankets presented an explosion risk to firefighters operating near the vehicle. The risk of an explosion can be increased when re-introducing air into an oxygen-depleted accumulation of unburned flammable battery gases. FPRF is conducting research to improve the safety of firefighters responding to electric vehicle (EV) fires and incidents by assessing current firefighting tactics and tools used by the fire service to manage EV incidents and the impact of suppression activities on managing re-ignition risks. Recent experiments for the Assessment of EV Firefighting Tactics, Tools and the Impact on Stranded Energy research project were conducted to assess the ability of four firefighting tactics to suppress and establish control of fire incidents involving standalone electric vehicle battery packs and full electric vehicles with confirmed battery pack fire involvement: standard hose stream application – water only; standard hose stream application – with injected agent; electric vehicle fire blankets; and firefighting appliances. Analysis of the data from FPRF experiments is underway. Preliminary results will be presented at the annual NFPA Conference and Expo on June 16, 2025 in Las Vegas and the full analysis will be provided in FPRF's forthcoming research report, which will be publicly available this fall at FSRI is conducting research to improve understanding of hazards generated by electric vehicle battery fires and to enable the development of firefighting tactics for effective electric vehicle fire control. Recent experiments for the Fire Safety of Batteries and Electric Vehicles research project were conducted to evaluate the capability of standard hose stream application, water application with an under-vehicle nozzle, and an electric vehicle fire blanket, to suppress and establish control of a burning electric vehicle with confirmed battery pack fire involvement. Analysis of the video and data from FSRI experiments is underway and will be addressed in detail in FSRI's forthcoming electric vehicle research report, which will be available at About Fire Protection Research FoundationThe Fire Protection Research Foundation is the research affiliate of NFPA. The Foundation is an independent nonprofit whose mission is to plan, manage, and communicate research in support of the association's mission to help save lives and reduce loss with information, knowledge and passion. The FPRF facilitates research on a broad range of fire safety issues in collaboration with scientists and laboratories around the world. About Fire Safety Research InstituteThe Fire Safety Research Institute (FSRI), part of UL Research Institutes, advances fire safety knowledge to address the world's unresolved fire safety risks and emerging dangers. As part of UL Research Institutes, we are committed to sharing our fire safety insights with everyone to advance UL's public safety mission of providing safe living and working environments for people everywhere. Through advanced fire science, rigorous research, extensive outreach and education in collaboration with our international network of partners, we impart stakeholders with the information, tools and resources that enable them to make better, more fire-safe decisions that ultimately save lives and property. Learn more at About UL Research InstitutesUL Research Institutes is a nonprofit research organization dedicated to advancing public safety through scientific discovery. Since 1894, our research has advanced our mission toward a safer, more secure, and sustainable future. Focused on global risks from fire mitigation and air quality to safe energy storage and digital privacy, we conduct rigorous independent research, analyze safety data, and partner with experts to uncover and act on existing and emerging risks to human safety. Discover more at View original content to download multimedia: SOURCE FSRI

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma
Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma

Associated Press

time14-05-2025

  • Associated Press

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma

Results Reinforce the Current Australian Oncology Clinical Trial and Support Investigation of the Hemopurifier Across Multiple Indications SAN DIEGO, May 14, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the publication ( ) of a pre-clinical ex vivo study in pre-print vehicle bioRxiv, entitled, 'Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device containing a Galanthus nivalis agglutinin (GNA) affinity resin.' Aethlon Medical's Hemopurifier® is a therapeutic blood filtration system designed to bind and remove harmful extracellular vesicles (EVs or exosomes) and life-threatening viruses from blood and other biological fluids, properties that support its evaluation not only in oncology and infectious diseases, but also in the organ transplantation and other areas of significant unmet medical need. Platelet-derived extracellular vesicles (PD-EVs) are the most numerous EV population in the body and are released by platelets in response to a variety of stimuli. The cargo contained within these EVs have been noted to participate in damage to blood vessels, activation of immune cells, and spread of tumor cells. Excessive levels of PD-EVs have been implicated in a myriad of diseases, including cancer, lupus, systemic sclerosis, multiple sclerosis, Alzheimer's disease, sepsis, acute and Long COVID. An independent research team had demonstrated that PD-EVs in Alzheimer's patients bound to the plant lectin Galanthus nivalis agglutinin (GNA). We hypothesized that the Aethlon Hemopurifier, which contains a proprietary GNA affinity resin would remove platelet derived EVs from plasma. In this experiment two hundred milliliters of donated healthy human plasma were circulated over the Aethlon Hemoupurifier (HP) to simulate a clinical HP session. The study results indicated a 98.5% removal of platelet -derived EVs at a timepoint equivalent to a 4-hour HP treatment. 'The data from this ex vivo study is exciting because it demonstrated for the first time that our device removes Platelet-derived EV's. This data is also supportive of our ongoing Oncology clinical trial in Australia as PD-EVs participate in the spread of cancers. We will be specifically looking at PD-EV removal in our subjects enrolled in the clinical trial,' said Steven P. LaRosa, MD, Chief Medical Officer at Aethlon Medical and senior author on the paper. 'Beyond Oncology we could envision many indications where removal of PD-EVs by the Hemopurifier could be a therapeutic strategy. The findings from this study raise the possibility of a 'pipeline within a device,' said James Frakes, Chief Executive Officer at Aethlon. Next steps will be to submit the findings of this study to a peer-review medical journal and specifically study PD-EV removal and their cargo from plasma samples from diseases of interest. About Aethlon and the Hemopurifier® Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies. Additional information can be found at Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as 'may,' 'believe,' 'anticipate,' 'expect,' 'intend,' 'plan,' 'project,' 'will,' 'projections,' 'estimate,' 'potentially' or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital and to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the ability of the Hemopurifier to continue to show removal of platelet -derived EVs at a timepoint equivalent to a 4-hour HP treatment; the Company's ability to achieve and realize the anticipated benefits from potential milestones; the Company's ability to submit applications to and obtain approval from the additional Ethics Committees in Australia and India, including on the timing expected by the Company; the Company's ability to initiate and continue its planned oncology clinical trials in Australia and India, including on the timing expected by the Company; the Company's ability to manage and successfully complete its clinical trials, if initiated; the potential impact of Hemopurifier on the H5N1 Avian Influenza (H5N1 HPAI) virus in dairy cattle; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials, and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended March 31, 2024, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Company Contact: Jim Frakes Interim Chief Executive Officer and Chief Financial Officer Aethlon Medical, Inc. [email protected] Investor Contact: Susan Noonan S.A. Noonan Communications, LLC [email protected] 917-513-5303 View original content: SOURCE Aethlon Medical, Inc.

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma
Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma

Yahoo

time14-05-2025

  • Yahoo

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma

Results Reinforce the Current Australian Oncology Clinical Trial and Support Investigation of the Hemopurifier Across Multiple Indications SAN DIEGO, May 14, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the publication ( of a pre-clinical ex vivo study in pre-print vehicle bioRxiv, entitled, "Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device containing a Galanthus nivalis agglutinin (GNA) affinity resin." Aethlon Medical's Hemopurifier® is a therapeutic blood filtration system designed to bind and remove harmful extracellular vesicles (EVs or exosomes) and life-threatening viruses from blood and other biological fluids, properties that support its evaluation not only in oncology and infectious diseases, but also in the organ transplantation and other areas of significant unmet medical need. Platelet-derived extracellular vesicles (PD-EVs) are the most numerous EV population in the body and are released by platelets in response to a variety of stimuli. The cargo contained within these EVs have been noted to participate in damage to blood vessels, activation of immune cells, and spread of tumor cells. Excessive levels of PD-EVs have been implicated in a myriad of diseases, including cancer, lupus, systemic sclerosis, multiple sclerosis, Alzheimer's disease, sepsis, acute and Long COVID. An independent research team had demonstrated that PD-EVs in Alzheimer's patients bound to the plant lectin Galanthus nivalis agglutinin (GNA). We hypothesized that the Aethlon Hemopurifier, which contains a proprietary GNA affinity resin would remove platelet derived EVs from plasma. In this experiment two hundred milliliters of donated healthy human plasma were circulated over the Aethlon Hemoupurifier (HP) to simulate a clinical HP session. The study results indicated a 98.5% removal of platelet -derived EVs at a timepoint equivalent to a 4-hour HP treatment. "The data from this ex vivo study is exciting because it demonstrated for the first time that our device removes Platelet-derived EV's. This data is also supportive of our ongoing Oncology clinical trial in Australia as PD-EVs participate in the spread of cancers. We will be specifically looking at PD-EV removal in our subjects enrolled in the clinical trial," said Steven P. LaRosa, MD, Chief Medical Officer at Aethlon Medical and senior author on the paper. "Beyond Oncology we could envision many indications where removal of PD-EVs by the Hemopurifier could be a therapeutic strategy. The findings from this study raise the possibility of a "pipeline within a device," said James Frakes, Chief Executive Officer at Aethlon. Next steps will be to submit the findings of this study to a peer-review medical journal and specifically study PD-EV removal and their cargo from plasma samples from diseases of interest. About Aethlon and the Hemopurifier®Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies. Additional information can be found at Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital and to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the ability of the Hemopurifier to continue to show removal of platelet -derived EVs at a timepoint equivalent to a 4-hour HP treatment; the Company's ability to achieve and realize the anticipated benefits from potential milestones; the Company's ability to submit applications to and obtain approval from the additional Ethics Committees in Australia and India, including on the timing expected by the Company; the Company's ability to initiate and continue its planned oncology clinical trials in Australia and India, including on the timing expected by the Company; the Company's ability to manage and successfully complete its clinical trials, if initiated; the potential impact of Hemopurifier on the H5N1 Avian Influenza (H5N1 HPAI) virus in dairy cattle; the Company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials, and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2024, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Company Contact:Jim FrakesInterim Chief Executive Officer and Chief Financial OfficerAethlon Medical, Inc. Jfrakes@ Investor Contact:Susan NoonanS.A. Noonan Communications, LLCsusan@ 917-513-5303 View original content: SOURCE Aethlon Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store